TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07905105: A Randomized, Double-blind, Single-dose, Placebo-controlled Pharmacokinetic and Proof-of-concept Study to Evaluate the Safety of CYT-1010 in Healthy Volunteers and in Subjects With Moderate to Severe Pain After Third Mol

Sponsor: Cytogel Pharma, LLC · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,030,400

Rescue Site Savings

+$5,954,420

Unlock Full NCT07905105 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07905105 Rescue Dossier →